The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Gain Therapeutics. This endorsement likely reflects confidence in the company's future performance and growth potential, which could positively influence investor sentiment and potentially drive up the stock price in the short term.